摘要
目的:观察肝缺血/再灌注损伤时血栓素B2(Thromboxane B2,TXB2)、前列环素F1α(Prostaglandin F1α,PGF1α)、TXB2/PGF1α比值变化和人参多糖的干预作用。方法:30只家免,随机均分为对照组(C组)、缺血/再灌注组(IR组)和人参多糖组(GP组)。分别检测三组缺血前10min、缺血45min及再灌注45min后血浆中TXB2、PGF1α、ALT及TXB2/PGF1α比值的变化,电镜下观察肝细胞超微结构的改变。结果:IR组血浆TXB2各对应时间点浓度均较C组明显升高,PGF1α含量再灌注45min时较缺血前显著下降,TXB2/PGF1α比值明显增高,肝细胞超微结构显著异常。使用人参多糖注射液后,血浆TXB2浓度较IR组同期水平降低,PGF1α再灌注45min显著高于IR组同期水平,TXB2/PGF1α显著低于IR组,尤以再灌注45min为著,肝细胞超微结构异常较IR组有所减轻。结论:人参多糖可通过调节TXB2/PGF1α之间的平衡,改善肝脏微循环,从而防治肝缺血/再灌注损伤。
To explore the influence of Ginseng Polysauharides on balance between Thromboxance B2 and Prostacyclin F1, during hepatic ischemia/reperfusion injury （HIRI） in rabbits. METHODS： Thirty rabbits were ran- domly divided into 3 groups： control group （Group C） ,ischemia/ reperfusion group （Group IR） and Ginseng Polysauharides group （Group GP）. Thromboxance B2 （TXB2）, Prostacy- clinFlo（PGFlo）, TXB2/PGF1a and ALT of the three groups were measured in 10 minutes beforeischemia, ischemia of 45 minutes and reperfusion after 45 minutes respectively, and the hepatocel- lular morphological changes were observed dur- ing HIRI in the electronic microscope. RE- SULTS： In Group IR, the content of TXB2 in the plasma was obviously higher than that in Group C in the corresponding time point; the content of PGF1a declined notably 45 minutes after reperfu- sion compared with 10 minutes before ischimia,TXB2/PGF1a increased significantly, the ultra- structure of hepatic cell was obviously abnor- mal. In Group GP, the content of TXB2 declined a little and the PGFlo increased compared with those in Group IR during reperfusion 45 mi- nutes. TXB2/PGF1a were significantly higher than the ratio of Group IR, especially 45 mi-nutes after reperfusion. The abnormal morpho- logical changes of liver cells was ameliorated re- markably too during HIRI. CONCLUSION： Gin- seng Polysauharides can regulate imbalance be- tween TXB2 and PGF1a, and improve hepatic mi- erocirculation, thus can prevent the hepatoeell from the injury caused by hepatic ischemia reper- fusion.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2012年第5期513-516,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
温州市科技计划项目(Y20060195)
